Clinical trials: Visually Impaired Persons
Ulcerative Colitis
A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission
Participants who were in clinical remission on 200 milligram (mg) filgotinib once daily for at least 2 consecutive quarterly visits in the ongoing SELECTION-LTE study (GS-US-418-3899, NCT02914535), were planned to be rolled over…
- Trial name
- CAPYBARA (NCT05479058)
- Testing
- Filgotinib
- Where
- 50 sites in United States, Belgium and 11 more
- Volunteers
- 22 people
- Sponsor
- Lakefront Biotherapeutics NV
Psoriasis
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
Plaque psoriasis is a chronic relapsing inflammatory skin disease that is characterized by keratinocyte hyper-proliferation and epidermal hyperplasia.
- Trial name
- NCT04316585
- Testing
- GSK2982772
- Where
- 9 sites in Canada, Poland
- Volunteers
- 29 people
- Sponsor
- GlaxoSmithKline
Lymphoma, Non-Hodgkin
Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
This was a randomized, double-blind, active-controlled, multiple-dose, clinical similarity study to evaluate the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability and immunogenicity of ABP 798 compared with…
- Trial name
- JASMINE (NCT02747043)
- Testing
- ABP 798, Rituximab
- Where
- 98 sites in United States, Australia and 18 more
- Volunteers
- 256 people
- Sponsor
- Amgen
Renal Impairment
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
The purpose of this study is to determine the effect of febuxostat, once daily (QD) or twice daily (BID), on renal function in gout patients with elevated serum urate levels and who have moderate to severe renal impairment.
- Trial name
- NCT01082640
- Testing
- Febuxostat
- Where
- 58 sites in United States
- Volunteers
- 96 people
- Sponsor
- Takeda
Locally Advanced Rectal Cancer
Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer
The main purpose of the study was to define maximum tolerated dose (MTD), recommended Phase II dose (RP2D) safety and tolerability of Peposertib in combination with capecitabine and radiotherapy (RT).
- Trial name
- NCT03770689
- Testing
- Peposertib 50 mg, Peposertib 100 mg, Peposertib 150 mg
- Where
- 14 sites in United States, Spain
- Volunteers
- 19 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Alport Syndrome
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome
Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function. To assess the safety and tolerability of lademirsen (SAR339375) in participants with Alport syndrome.
- Trial name
- HERA (NCT02855268)
- Testing
- lademirsen (SAR339375)
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 43 people
- Sponsor
- Genzyme, a Sanofi Company
Fibromyalgia
A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia
The primary objective of the study is to estimate the treatment effect of fremanezumab administered subcutaneously (SC) in reducing pain in adult participants with fibromyalgia (FM).
- Trial name
- NCT03965091
- Testing
- Fremanezumab
- Where
- 49 sites in United States
- Volunteers
- 189 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Hypertension
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.
- Trial name
- NCT00765674
- Testing
- Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ)
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 1,191 people
- Sponsor
- Novartis
Acne Vulgaris
Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris
The objective of this study is to assess safety and efficacy of various doses of BTX 1503 liquid formulation in subjects with moderate to severe acne vulgaris of the face.
- Trial name
- NCT03573518
- Testing
- BTX 1503, Vehicle
- Where
- 36 sites in United States, Australia
- Volunteers
- 368 people
- Sponsor
- Botanix Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the safety and efficacy of QVA149 in patients with moderate to severe COPD.
- Trial name
- NCT00570778
- Testing
- indacaterol/glycopyrrolate, indacaterol
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 154 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Memory Disorders
Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment
The purpose of the study is to determine the safety, tolerability, and effectiveness of 2 dose levels of LX6171 given over 28 days in patients with Age Associated Memory Impairment (AAMI).
- Trial name
- NCT00691808
- Testing
- LX6171 High Dose, LX6171 Low Dose
- Where
- 2 sites in Netherlands
- Volunteers
- 103 people
- Sponsor
- Lexicon Pharmaceuticals
Tuberculosis
Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of single and then multiple doses of MK-7762 (TBD09) in healthy volunteers in the context of a first-in-human study.
- Trial name
- NCT05824091
- Testing
- MK-7762 (TBD09)
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Obsessive-compulsive Disorder, Ocd
Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
Obsessive-compulsive disorder (OCD) affects 2-3% of the population and leads to a great deal of suffering. Many patients benefit from established treatments, the mainstay of which are cognitive behavioral therapy and a group of…
- Trial name
- NCT00523718
- Testing
- riluzole
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yale University
Atopic Dermatitis
Study of OPA-15406 Ointment in Patients With Atopic Dermatitis
The purpose of this study is to assess the efficacy and safety of OPA-15406 ointment in patients with atopic dermatitis.
- Trial name
- NCT02914548
- Testing
- OPA-15406
- Where
- 3 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Ovarian Cancer
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
This two-part, multicenter study will evaluate the safety, tolerability and efficacy of pertuzumab in combination with standard chemotherapy in women with recurrent platinum-resistant epithelial ovarian cancer.
- Trial name
- NCT01684878
- Testing
- Gemcitabine (Chemotherapy), Paclitaxel (Chemotherapy), Pertuzumab
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease: COPD
Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.
The study purpose is to evaluate the effect of QAB149 NVA237 vs. QAB149 on static lung hyperinflation.
- Trial name
- SYNERGY (NCT01699685)
- Testing
- QAB149, NVA237
- Where
- 11 sites in Switzerland
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Scabies
Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.
This is a multi-center, double-blind, randomized, two arm parallel design study. This study is comprised of two phases: screening and treatment.
- Trial name
- NCT02978508
- Testing
- Permethrin Cream, 5%, Elimite
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- Mayne Pharma International Pty Ltd
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553591
- Testing
- Eluxadoline
- Where
- 283 sites in United States, Canada and 1 more
- Volunteers
- 1,282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Schizophrenia
A Study in Schizophrenic Patients
This study is designed to compare 3 doses of LY2140023 for the treatment of schizophrenia as assessed at endpoint (up to 7 weeks) using the Clinical Utility Index (CUI), a measure of efficacy, safety, and tolerability.
- Trial name
- NCT01125358
- Testing
- LY2140023
- Where
- 22 sites in Japan, South Korea and 1 more
- Volunteers
- 82 people
- Sponsor
- Denovo Biopharma LLC
Healthy
Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution
The purpose of this study is to compare subjective drug liking using the Drug Rating Questionnaire, subject version (DRQ-S), question 2 and pharmacokinetics of Vyvanse™ and ADDERALL XR® when administered as an oral solution.
- Trial name
- NCT00776555
- Testing
- Lisdexamfetamine Dimesylate, Racemic mixture of dextroamphetamine and lisdexamfetamine
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Shire